Publicaciones en colaboración con investigadores/as de University of Rostock (22)

2024

  1. Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study

    European Journal of Cancer, Vol. 196

2022

  1. Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial

    Frontiers in Oncology, Vol. 12

  2. Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients

    European Journal of Cancer, Vol. 166, pp. 185-201

  3. The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021

    Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 28, Núm. 9, pp. 1424-1456

2021

  1. Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel

    Alzheimer's and Dementia, Vol. 17, Núm. 9, pp. 1528-1553

  2. Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 14, pp. 1518-1530

2020

  1. Characteristics and treatment regimens across ERS SHARP severe asthma registries

    European Respiratory Journal, Vol. 55, Núm. 1

  2. What electrophysiology tells us about Alzheimer's disease: a window into the synchronization and connectivity of brain neurons

    Neurobiology of Aging, Vol. 85, pp. 58-73

2019

  1. First Report of Edge Vascular Response at 12 Months of Magmaris, A Second-Generation Drug-Eluting Resorbable Magnesium Scaffold, Assessed by Grayscale Intravascular Ultrasound, Virtual Histology, and Optical Coherence Tomography. A Biosolve-II Trial Sub-Study

    Cardiovascular Revascularization Medicine, Vol. 20, Núm. 5, pp. 392-398

2017

  1. Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts

    CNS Drugs, Vol. 31, Núm. 1, pp. 33-50

  2. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

2016

  1. Analysis of plasminogen genetic variants in multiple sclerosis patients

    G3: Genes, Genomes, Genetics, Vol. 6, Núm. 7, pp. 2073-2079

2015

  1. Genome-wide significant association with seven novel multiple sclerosis risk loci

    Journal of Medical Genetics, Vol. 52, Núm. 12, pp. 848-855

2013

  1. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: The RELIEF trial

    Hepatology, Vol. 57, Núm. 3, pp. 1153-1162

  2. MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis

    Brain, Vol. 136, Núm. 6, pp. 1778-1782

2012

  1. Analysis of the IL28RA locus as genetic risk factor for multiple sclerosis

    Journal of Neuroimmunology, Vol. 245, Núm. 1-2, pp. 98-101

  2. Closing the case of APOE in multiple sclerosis: No association with disease risk in over 29 000 subjects

    Journal of Medical Genetics, Vol. 49, Núm. 9, pp. 558-562

  3. Thoracic Endovascular Aortic Repair (TEVAR) for the treatment of aortic diseases: A position statement from the European Association for Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

    European Heart Journal, Vol. 33, Núm. 13, pp. 1558-1563

  4. Thoracic endovascular aortic repair (TEVAR) for the treatment of aortic diseases: A position statement from the european association for cardio-thoracic surgery (EACTS) and the european society of cardiology (ESC), in collaboration with the european association of percutaneous cardiovascular interventions (EAPCI)

    European Journal of Cardio-thoracic Surgery, Vol. 42, Núm. 1, pp. 17-24

2011

  1. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: An open-label, randomised phase 2/3 trial

    The Lancet Infectious Diseases, Vol. 11, Núm. 4, pp. 273-283